Core Insights - Perrigo (PRGO) reported adjusted earnings of 60 cents per share for Q1 2025, exceeding the Zacks Consensus Estimate of 56 cents, marking a 107% year-over-year increase driven by improved margins and lower variable expenses [1] - Net sales for the quarter declined 3.5% year over year to $1.04 billion, falling short of the Zacks Consensus Estimate of $1.08 billion, primarily due to exited businesses, product lines, and unfavorable currency movements [1][2] Financial Performance - Sales dropped 2% year over year due to exited businesses and product lines, with an additional 1.2% decline attributed to unfavorable currency movements; at constant currency, sales fell 2.4% [2] - Organic net sales decreased by 0.4%, indicating a slight decline in core business performance [2] Segment Analysis - Consumer Self Care Americas (CSCA): Reported net sales of $621 million, down 3.6% year over year; growth in Nutrition and Upper Respiratory categories was offset by lost distribution in U.S. Store Brand and lower sales in Digestive Health [4] - Consumer Self Care International (CSCI): Reported net sales of $423 million, down 3.4% year over year; organic sales increased by 4.5%, but overall sales were impacted by divested businesses and currency translation [5] Guidance and Outlook - Perrigo widened its full-year sales outlook to a growth range of 0-3% year over year, compared to the previous guidance of 1-3%, due to macroeconomic uncertainties including potential new tariffs [6] - The company plans to manage cost increases from tariffs, particularly in the Oral Care segment, through price adjustments and shifting production to domestic facilities [7] Stock Performance - Year to date, Perrigo shares have declined by 4%, contrasting with the industry’s 4% growth [8]
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y